V
Valeriya Baru
Researcher at Massachusetts Institute of Technology
Publications - 14
Citations - 1495
Valeriya Baru is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Endocytic cycle & Induced pluripotent stem cell. The author has an hindex of 10, co-authored 12 publications receiving 1120 citations.
Papers
More filters
Journal ArticleDOI
Identification and Rescue of α-Synuclein Toxicity in Parkinson Patient–Derived Neurons
Chee Yeun Chung,Vikram Khurana,Vikram Khurana,Pavan K. Auluck,Pavan K. Auluck,Daniel F. Tardiff,Joseph R. Mazzulli,Frank Soldner,Valeriya Baru,Yali Lou,Yelena Freyzon,Sukhee Cho,Alison E. Mungenast,Julien Muffat,Maisam Mitalipova,Michael D. Pluth,Nathan T. Jui,Birgitt Schüle,Stephen J. Lippard,Li-Huei Tsai,Li-Huei Tsai,Dimitri Krainc,Stephen L. Buchwald,Rudolf Jaenisch,Susan Lindquist +24 more
TL;DR: In this paper, the authors exploited mutation correction of iPS cells and conserved proteotoxic mechanisms from yeast to humans to discover and reverse phenotypic responses to α-synuclein (αsyn), a key protein involved in Parkinson's disease (PD).
Journal ArticleDOI
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast
Sebastian Treusch,Shusei Hamamichi,Shusei Hamamichi,Jessica L. Goodman,Kent E. S. Matlack,Chee Yeun Chung,Valeriya Baru,Joshua M. Shulman,Joshua M. Shulman,Antonio R. Parrado,Brooke J. Bevis,Julie S. Valastyan,Haesun Han,Malin Lindhagen-Persson,Eric M. Reiman,Eric M. Reiman,Denis A. Evans,David A. Bennett,Anders Olofsson,Philip L. DeJager,Philip L. DeJager,Rudolph E. Tanzi,Kim A. Caldwell,Guy A. Caldwell,Susan Lindquist +24 more
TL;DR: In this article, the authors showed that β-amyloid peptide is an important contributor to Alzheimer's disease (AD) by directing the peptide to the secretory pathway.
Journal ArticleDOI
Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment
Saranna Fanning,Saranna Fanning,Aftabul Haque,Thibaut Imberdis,Valeriya Baru,M. Inmaculada Barrasa,Silke Nuber,Daniel Termine,Nagendran Ramalingam,Gary P.H. Ho,Tallie Noble,Jackson Sandoe,Yali Lou,Dirk Landgraf,Yelena Freyzon,Gregory A. Newby,Frank Soldner,Elizabeth Terry-Kantor,Tae-Eun Kim,Harald F. Hofbauer,Michel Becuwe,Rudolf Jaenisch,David Pincus,Clary B. Clish,Tobias C. Walther,Robert V. Farese,Supriya Srinivasan,Supriya Srinivasan,Michael A. Welte,Sepp D. Kohlwein,Ulf Dettmer,Susan Lindquist,Dennis J. Selkoe +32 more
TL;DR: Monounsaturated fatty acid metabolism is pivotal for αS-induced neurotoxicity, and inhibiting SCD represents a novel PD therapeutic approach.
Journal ArticleDOI
Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways
Vikram Khurana,Vikram Khurana,Vikram Khurana,Jian Peng,Chee Yeun Chung,Pavan K. Auluck,Saranna Fanning,Daniel F. Tardiff,Theresa Bartels,Martina Koeva,Stephen W. Eichhorn,Hadar Benyamini,Yali Lou,Andy Nutter-Upham,Valeriya Baru,Yelena Freyzon,Nurcan Tuncbag,Michael Costanzo,Bryan Joseph San Luis,David C. Schöndorf,M. Inmaculada Barrasa,Sepehr Ehsani,Neville E. Sanjana,Neville E. Sanjana,Quan Zhong,Thomas Gasser,David P. Bartel,Marc Vidal,Michela Deleidi,Charles Boone,Ernest Fraenkel,Bonnie Berger,Susan Lindquist +32 more
TL;DR: This cross-species platform connected diverse neurodegenerative genes to proteinopathy through specific mechanisms and may facilitate patient stratification for targeted therapy.
Journal ArticleDOI
Calcineurin determines toxic versus beneficial responses to α-synuclein
Gabriela Caraveo,Pavan K. Auluck,Pavan K. Auluck,Pavan K. Auluck,Luke Whitesell,Chee Yeun Chung,Valeriya Baru,Eugene V. Mosharov,Xiaohui Yan,Manu Ben-Johny,Martin Soste,Paola Picotti,Hanna Kim,Kim A. Caldwell,Guy A. Caldwell,David Sulzer,David T. Yue,Susan Lindquist +17 more
TL;DR: A tunable response to CN, which has been conserved for a billion years, can be targeted to rebalance the phosphatase’s activities from toxic toward beneficial substrates, and have immediate therapeutic implications for synucleinopathies.